Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label perioperative SHR-A2009 combination therapy study in resectable non-small cell lung cancer
CTR20263787Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Oct 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ruzaltatug rezetecan in non-small cell lung cancer (NSCLC), bronchial carcinoma, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Oct 2026; status: active.
02
Drugs
ruzaltatug rezetecan
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on CTR20263787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263787.